The company posted their 3rd quarter results today. The financial performance of the company is accelerating with a significant increase in overall profitability. Net income was 8.25% of revenue and is approaching a level that is consistent with a successful medical device company. All aspects of the business, except for Europe and Asia, performed very well. With prospects of new products coming to market in the near future and continued focused marketing and sales initiatives I expect the equity price to continue to advance. Recent volume and price action of the stock indicates increased investor interest in this company. This fiscal year has confirmed the turnaround of the company and now it is establishing itself as profitable and growing medical device company that is currently very undervalued. The strength of the Executives, the management team, and the employee base is showing itself in the positive results just released.